Lung Cancer
A comprehensive, evidence-based guide to lung cancer types, staging, biomarkers, screening, treatment options, side effects, and questions to ask your care team. Plain language. Every claim cited.
Quick Overview
Key facts about lung cancer that everyone should know.
New Cases Per Year
Approximately 2.2 million new lung cancer cases are diagnosed globally each year, making it one of the most common cancers worldwide. [WHO]
Leading Cause of Cancer Death
Lung cancer is the leading cause of cancer-related death globally for both men and women, accounting for roughly 1.8 million deaths annually. [WHO]
Two Main Types
Non-small cell lung cancer (NSCLC) accounts for about 85% of cases. Small cell lung cancer (SCLC) accounts for about 15% and is faster growing. [ACS]
Screening Saves Lives
Low-dose CT screening for high-risk individuals has been shown to reduce lung cancer mortality by up to 20%. Early detection changes outcomes. [USPSTF]
Treatments Advancing Rapidly
Targeted therapies and immunotherapies have transformed lung cancer treatment, with many patients now living longer and better than ever before. [NCI]
What Is Lung Cancer?
Lung cancer is a disease in which cells in the lung grow abnormally and uncontrollably, forming tumors that can interfere with the lung's ability to provide oxygen to the body through the bloodstream. It can start in the airways (bronchi), the smaller airways (bronchioles), or the tiny air sacs (alveoli) deep inside the lungs. [NCI]
In healthy lungs, cells grow, divide, and die in an orderly way. When this process goes wrong — usually because of damage to the DNA inside cells — cells can begin to grow out of control. Over time, these abnormal cells can form a mass (tumor) and can spread to nearby lymph nodes or other parts of the body, a process called metastasis. [ACS]
How Lung Cancer Develops
Lung cancer usually develops over many years. The cells lining the airways are repeatedly exposed to harmful substances — most commonly from cigarette smoke — that damage the DNA within those cells. Early on, the body may be able to repair this damage. But with continued exposure, the damage accumulates and normal cells gradually become precancerous, and eventually cancerous. It is worth noting that lung cancer can also occur in people who have never smoked. In fact, an estimated 10–20% of lung cancers occur in never-smokers, often driven by genetic mutations, radon exposure, or other environmental factors. [Herbst RS, et al., 2018]
Risk Factors
Several factors can increase the chance of developing lung cancer. Understanding these can help with prevention, early detection, and reducing stigma:
- Tobacco smoking: The single largest risk factor. Smoking causes about 80–90% of lung cancer deaths. The risk increases with the number of cigarettes smoked per day and the number of years smoked. Cigar and pipe smoking also increase risk. [ACS]
- Secondhand smoke: Breathing in other people's smoke increases the risk of lung cancer in non-smokers by 20–30%. [ACS]
- Radon exposure: Radon is a naturally occurring radioactive gas that can accumulate in homes and buildings. It is the second leading cause of lung cancer and the leading cause in non-smokers. [ALA]
- Asbestos and occupational exposures: Workplace exposure to asbestos, arsenic, diesel exhaust, chromium, nickel, and certain other substances can increase lung cancer risk, especially in combination with smoking. [NCI]
- Air pollution: Long-term exposure to high levels of air pollution — particularly fine particulate matter (PM2.5) — is associated with an increased risk of lung cancer. [WHO]
- Previous radiation therapy: People who have received radiation therapy to the chest for other cancers (such as Hodgkin lymphoma or breast cancer) have a higher risk. [ACS]
- Family history and genetics: Having a first-degree relative (parent, sibling, or child) with lung cancer increases your risk, even after accounting for smoking. Certain inherited genetic variations may also play a role. [NCI]
- Personal history of lung disease: Conditions like chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis are associated with a higher risk of lung cancer. [ACS]
Types of Lung Cancer
Lung cancer is classified by how the cancer cells look under a microscope. The type determines treatment strategy and likely behavior.
Non-Small Cell Lung Cancer (NSCLC)
NSCLC is the most common form of lung cancer. It tends to grow and spread more slowly than small cell lung cancer, though this varies by subtype. NSCLC includes three main subtypes: [ACS]
The most common subtype, accounting for about 40% of all lung cancers. It starts in the cells that line the alveoli (air sacs) and produce mucus. Adenocarcinoma is the most common type found in non-smokers and in younger patients. It is usually found in the outer parts of the lung. [NCI]
Accounts for about 25–30% of lung cancers. It begins in the flat cells (squamous cells) lining the airways and is strongly linked to smoking. It is often found in the central part of the lungs, near a main bronchus. [ACS]
Accounts for about 10–15% of lung cancers. It can appear in any part of the lung and tends to grow and spread quickly. A variant called large cell neuroendocrine carcinoma is similar to small cell lung cancer in behavior. [NCI]
Small Cell Lung Cancer (SCLC)
SCLC is a fast-growing type of lung cancer that almost always occurs in heavy smokers. It tends to spread quickly to other parts of the body, often before it is diagnosed. Because of this, it is usually treated with chemotherapy and radiation rather than surgery. SCLC is staged differently from NSCLC — as either "limited stage" (confined to one side of the chest) or "extensive stage" (spread beyond one side of the chest). Despite its aggressive nature, SCLC often responds well to initial treatment, though it frequently recurs. [ACS, NCI]
Lung Carcinoid Tumors
Carcinoid tumors account for fewer than 5% of lung tumors. They are neuroendocrine tumors — meaning they develop from cells of the neuroendocrine system. Lung carcinoids are divided into typical carcinoids (slow-growing, rarely spread) and atypical carcinoids (slightly faster-growing, more likely to spread). They are generally considered less aggressive than NSCLC or SCLC. Treatment often involves surgery when possible. [ACS]
Symptoms & Early Signs
Lung cancer often causes no symptoms in its earliest stages. When symptoms do appear, they may be mistaken for other conditions. If any of the following persist, consult your doctor. [ACS]
Screening for Lung Cancer
Lung cancer screening uses a low-dose computed tomography scan (LDCT) to look for lung cancer in people who are at high risk but do not yet have symptoms. Unlike a regular chest X-ray, LDCT can detect very small nodules in the lungs that may be early-stage cancer. [USPSTF]
Who Should Be Screened?
The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for people who meet all three of these criteria: [USPSTF]
- Age 50 to 80 years old
- Have a 20 pack-year smoking history or more (a pack-year is calculated by multiplying the number of packs smoked per day by the number of years smoked — for example, 1 pack per day for 20 years = 20 pack-years)
- Currently smoke or have quit within the past 15 years
Why Screening Matters
The National Lung Screening Trial (NLST) demonstrated that annual LDCT screening reduced lung cancer mortality by approximately 20% compared to chest X-ray screening in high-risk adults. The NELSON trial in Europe confirmed these findings with an even greater mortality reduction. When lung cancer is found at an early stage (Stage I), the 5-year survival rate is significantly higher than when found at later stages. [ALA, USPSTF]
Screening is not without limitations. False positives can lead to unnecessary follow-up tests, anxiety, and occasionally invasive procedures for nodules that turn out to be benign. Discuss the benefits and risks with your doctor to make an informed decision. [USPSTF]
Diagnosis & Testing
If your doctor suspects lung cancer — because of symptoms, an abnormal screening result, or an incidental finding on imaging — several tests may be performed to confirm the diagnosis, determine the type, and assess how far it has spread. [NCI]
Imaging Tests
- Chest X-ray: Often the first imaging test performed. It can reveal an abnormal mass or nodule in the lung, though it cannot confirm cancer on its own.
- CT scan (computed tomography): Provides detailed cross-sectional images of the lungs and can show the size, shape, and location of a tumor. CT scans can also reveal whether cancer has spread to lymph nodes or other structures in the chest.
- PET scan (positron emission tomography): Uses a small amount of radioactive glucose to identify areas of the body with high metabolic activity — cancer cells consume glucose more rapidly than normal cells. PET scans are often combined with CT scans (PET-CT) and help determine whether cancer has spread beyond the lungs.
- MRI (magnetic resonance imaging): May be used to look for cancer that has spread to the brain or spinal cord, particularly in patients with SCLC or advanced NSCLC.
- Bone scan: Used when there is concern that lung cancer may have spread to the bones.
Biopsy Procedures
A biopsy — removing a sample of tissue for examination under a microscope — is required to confirm a lung cancer diagnosis. There are several ways to obtain a biopsy: [NCI]
- Bronchoscopy: A thin, flexible tube with a camera (bronchoscope) is passed through the nose or mouth into the airways. The doctor can visualize the airways and take tissue samples from suspicious areas. Endobronchial ultrasound (EBUS) may be used to guide needle biopsies of lymph nodes near the airways.
- CT-guided needle biopsy: A needle is inserted through the chest wall into the tumor while CT imaging provides guidance. This is often used for tumors in the outer part of the lung that cannot be reached by bronchoscopy.
- Thoracentesis: If there is fluid around the lung (pleural effusion), a needle can be used to drain and analyze the fluid for cancer cells.
- Mediastinoscopy: A surgical procedure in which a small incision is made in the neck to examine and sample lymph nodes in the mediastinum (the area between the lungs).
- Surgical biopsy (thoracoscopy or thoracotomy): In some cases, a surgical procedure may be needed to obtain an adequate tissue sample, especially if other methods have been inconclusive.
Molecular and Biomarker Testing
Once lung cancer is confirmed, molecular testing (also called genomic or biomarker testing) of the tumor tissue is critically important, especially for NSCLC. These tests look for specific genetic mutations, rearrangements, and protein expression patterns that can guide treatment decisions. Key biomarkers include: [NCCN]
- EGFR mutations (epidermal growth factor receptor)
- ALK rearrangements (anaplastic lymphoma kinase)
- ROS1 rearrangements
- BRAF V600E mutations
- KRAS G12C mutations
- PD-L1 expression (programmed death-ligand 1)
- NTRK gene fusions
- MET exon 14 skipping mutations
- RET rearrangements
- HER2 (ERBB2) mutations
These results are essential because targeted therapies and immunotherapies are now available for many of these specific alterations. Without this testing, patients may miss effective treatment options. Testing can be performed on biopsy tissue or, in some cases, through a liquid biopsy (a blood test that detects circulating tumor DNA). [NCCN, Herbst RS, et al., 2018]
Staging
Staging describes how far a cancer has spread. It is one of the most important factors in determining treatment options and prognosis. NSCLC and SCLC use different staging systems. [ACS]
NSCLC Staging (TNM System)
NSCLC is staged using the TNM system, where T describes the size and extent of the primary tumor, N describes whether cancer has spread to nearby lymph nodes, and M describes whether the cancer has metastasized (spread) to distant parts of the body. These TNM values are combined to assign an overall stage: [ACS, NCI]
The cancer is small (usually 4 cm or less) and is found only in the lung. It has not spread to lymph nodes or distant sites. Stage I is further divided into IA (tumor 3 cm or less) and IB (tumor greater than 3 cm but 4 cm or less). Surgery is the primary treatment, and 5-year survival rates are the highest of all stages.
The tumor may be larger (up to 7 cm) and/or cancer has spread to nearby lymph nodes within the lung (hilar lymph nodes). It has not spread to distant sites. Stage II includes IIA and IIB. Surgery, often followed by chemotherapy (adjuvant chemotherapy), is the typical approach.
The cancer has spread to mediastinal lymph nodes (those in the center of the chest, between the lungs) or to nearby structures. Stage III is divided into IIIA, IIIB, and IIIC based on the extent of lymph node involvement and tumor spread. Some Stage IIIA cancers may be treated with surgery combined with chemotherapy and/or radiation. Many Stage III cancers are treated with concurrent chemotherapy and radiation (chemoradiation), sometimes followed by immunotherapy.
The cancer has spread to distant parts of the body — such as the other lung, brain, bones, liver, or adrenal glands. Stage IV is divided into IVA (spread to one distant site or malignant pleural/pericardial effusion) and IVB (multiple distant metastases). Treatment focuses on controlling the disease, managing symptoms, and extending life. This is where targeted therapies, immunotherapy, and combination approaches have made the greatest impact in recent years. [NCCN]
SCLC Staging
Small cell lung cancer uses a simpler two-stage system because it tends to spread early and is rarely treated with surgery: [ACS]
- Limited stage: The cancer is found in one lung and possibly nearby lymph nodes on the same side of the chest. It can be encompassed within a single radiation field. About one-third of people with SCLC are diagnosed at this stage. Treatment typically involves chemotherapy plus radiation therapy, and some patients may be cured.
- Extensive stage: The cancer has spread beyond one side of the chest — to the other lung, distant lymph nodes, or other organs. About two-thirds of SCLC patients are diagnosed at this stage. Treatment is primarily chemotherapy, often combined with immunotherapy. Radiation may be used for symptom relief or to prevent brain metastases.
Biomarkers & Molecular Testing
Molecular testing has transformed lung cancer treatment. By identifying specific genetic changes in a tumor, doctors can select therapies that precisely target those changes — often with better response rates and fewer side effects than traditional chemotherapy. This approach is called precision medicine or personalized medicine. [NCCN, Herbst RS, et al., 2018]
The following biomarkers are most commonly tested in NSCLC:
EGFR Mutations (Epidermal Growth Factor Receptor)
EGFR is a protein on the surface of cells that helps them grow. Certain mutations in the EGFR gene cause cells to grow uncontrollably. EGFR mutations are found in about 10–15% of NSCLC patients in Western countries and up to 50% in East Asian populations. They are most common in adenocarcinoma, non-smokers, and women. Targeted drugs called EGFR tyrosine kinase inhibitors (TKIs) — including osimertinib, erlotinib, and gefitinib — are the standard first-line treatment for EGFR-mutant NSCLC. [NCCN]
ALK Rearrangements (Anaplastic Lymphoma Kinase)
ALK rearrangements occur when the ALK gene fuses with another gene, producing an abnormal protein that drives cancer growth. This alteration is found in about 3–5% of NSCLC cases, most commonly in younger patients, non-smokers, and adenocarcinoma. ALK inhibitors such as alectinib, brigatinib, and lorlatinib have shown remarkable effectiveness. [NCCN]
ROS1 Rearrangements
ROS1 rearrangements are similar to ALK rearrangements and found in about 1–2% of NSCLC cases. They respond to several ALK inhibitors (particularly crizotinib and entrectinib). Testing is recommended for all advanced NSCLC patients. [NCCN]
BRAF V600E Mutations
BRAF V600E mutations occur in about 1–2% of NSCLC cases. The combination of dabrafenib and trametinib is an approved targeted therapy for this mutation. [NCCN]
KRAS G12C Mutations
KRAS mutations are among the most common oncogenic drivers in NSCLC, found in roughly 25% of adenocarcinomas. The specific KRAS G12C mutation (about 13% of adenocarcinomas) is now targetable with sotorasib and adagrasib. For decades, KRAS was considered "undruggable," so these new therapies represent a major breakthrough. [NCCN, Herbst RS, et al., 2018]
PD-L1 Expression
PD-L1 (programmed death-ligand 1) is a protein that can be expressed on cancer cells. When PD-L1 binds to PD-1 on immune cells, it essentially tells the immune system to leave the cancer cells alone. PD-L1 expression levels help determine whether a patient is likely to respond to immunotherapy. High PD-L1 expression (50% or greater) is associated with better responses to checkpoint inhibitors like pembrolizumab. However, some patients with low or even negative PD-L1 also benefit from immunotherapy, especially in combination with chemotherapy. [NCCN]
Tumor Mutational Burden (TMB)
TMB measures the total number of mutations in a tumor's DNA. Tumors with a high TMB may produce more abnormal proteins (neoantigens) that the immune system can recognize, potentially making them more responsive to immunotherapy. TMB is sometimes used alongside PD-L1 testing to help guide immunotherapy decisions, though its role is still evolving. [Herbst RS, et al., 2018]
Treatment Options
Treatment for lung cancer depends on the type (NSCLC vs. SCLC), the stage, the patient's overall health, lung function, and — critically for NSCLC — the molecular profile of the tumor. Treatment plans are typically developed by a multidisciplinary team including oncologists, surgeons, radiation oncologists, pulmonologists, and pathologists. [NCCN]
Surgery
Surgery is the primary treatment for early-stage NSCLC (Stages I and II) and selected Stage IIIA cases. The goal is to completely remove the tumor along with a margin of healthy tissue. Types of lung cancer surgery include: [NCI]
- Lobectomy: Removal of an entire lobe of the lung. The right lung has three lobes; the left has two. This is the most common and generally preferred surgical approach for lung cancer.
- Pneumonectomy: Removal of an entire lung. This is performed when the tumor's size or location makes a lobectomy insufficient.
- Segmentectomy or wedge resection: Removal of part of a lobe. These may be used for very small tumors or in patients who cannot tolerate a lobectomy due to limited lung function.
- Sleeve resection: Removal of a section of the bronchus along with the surrounding lobe, with reconnection of the remaining airway. This can sometimes preserve more lung tissue than a pneumonectomy.
Surgery may be performed using minimally invasive techniques (video-assisted thoracoscopic surgery, or VATS, and robotic-assisted surgery) when appropriate. These approaches typically result in less pain, shorter hospital stays, and faster recovery. [NCI]
Radiation Therapy
Radiation therapy uses high-energy beams to kill cancer cells. It may be used in several ways for lung cancer: [NCI]
- As primary treatment: For early-stage NSCLC patients who cannot have surgery, stereotactic body radiation therapy (SBRT) can deliver very precise, high-dose radiation to the tumor.
- After surgery (adjuvant): To kill any remaining cancer cells at the surgical site.
- With chemotherapy (concurrent chemoradiation): The standard approach for many Stage III NSCLC cases and limited-stage SCLC.
- For symptom relief (palliative): To shrink tumors that are causing pain, bleeding, or airway obstruction.
- Prophylactic cranial irradiation (PCI): Radiation to the brain to prevent brain metastases, sometimes used in SCLC that has responded well to treatment.
Chemotherapy
Chemotherapy uses drugs that kill rapidly dividing cells throughout the body. For lung cancer, common chemotherapy regimens include: [NCI, NCCN]
- NSCLC: Platinum-based doublets are the backbone — typically cisplatin or carboplatin combined with another drug such as pemetrexed (for non-squamous NSCLC), gemcitabine, docetaxel, or paclitaxel.
- SCLC: The standard regimen is etoposide plus a platinum agent (cisplatin or carboplatin), often combined with immunotherapy for extensive-stage disease.
Chemotherapy may be given before surgery (neoadjuvant — to shrink the tumor), after surgery (adjuvant — to reduce recurrence risk), or as the main treatment for advanced disease. It is given in cycles, with rest periods to allow the body to recover. [NCI]
Targeted Therapy
Targeted therapies are drugs designed to attack specific molecular changes that drive cancer growth. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies are more precise and often have different (sometimes fewer) side effects. Key targeted therapies for lung cancer include: [NCCN]
- EGFR inhibitors: Osimertinib (Tagrisso), erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif). Osimertinib is now the preferred first-line treatment for EGFR-mutant NSCLC.
- ALK inhibitors: Alectinib (Alecensa), brigatinib (Alunbrig), lorlatinib (Lorbrena), crizotinib (Xalkori), ceritinib (Zykadia).
- ROS1 inhibitors: Crizotinib, entrectinib (Rozlytrek).
- BRAF + MEK inhibitors: Dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600E mutations.
- KRAS G12C inhibitors: Sotorasib (Lumakras), adagrasib (Krazati).
- RET inhibitors: Selpercatinib (Retevmo), pralsetinib (Gavreto).
- MET inhibitors: Capmatinib (Tabrecta), tepotinib (Tepmetko) for MET exon 14 skipping mutations.
- NTRK inhibitors: Larotrectinib (Vitrakvi), entrectinib (Rozlytrek) for NTRK gene fusions.
Immunotherapy
Immunotherapy works by helping the body's own immune system recognize and attack cancer cells. Immune checkpoint inhibitors are the most widely used class in lung cancer. These drugs block proteins (PD-1, PD-L1, or CTLA-4) that cancer cells use to hide from the immune system: [NCCN, NCI]
- Pembrolizumab (Keytruda): A PD-1 inhibitor. Approved as first-line monotherapy for NSCLC with high PD-L1 expression (50% or greater), and in combination with chemotherapy for NSCLC regardless of PD-L1 level.
- Nivolumab (Opdivo): A PD-1 inhibitor. Used for NSCLC and, in combination with ipilimumab and chemotherapy, as first-line treatment.
- Atezolizumab (Tecentriq): A PD-L1 inhibitor. Used alone or in combination with chemotherapy and/or bevacizumab for NSCLC, and with chemotherapy for extensive-stage SCLC.
- Durvalumab (Imfinzi): A PD-L1 inhibitor. Used as consolidation therapy after chemoradiation for unresectable Stage III NSCLC (the PACIFIC regimen), and with chemotherapy for extensive-stage SCLC.
- Ipilimumab (Yervoy): A CTLA-4 inhibitor. Used in combination with nivolumab and chemotherapy for first-line treatment of metastatic NSCLC.
Combination Approaches
In modern lung cancer treatment, combining different treatment modalities is common and often more effective than any single approach: [NCCN]
- Chemoimmunotherapy: Combining chemotherapy with immunotherapy has become a standard first-line approach for advanced NSCLC without actionable driver mutations.
- Neoadjuvant immunotherapy + chemotherapy: Giving immunotherapy and chemotherapy before surgery (followed by adjuvant immunotherapy after surgery) is an emerging and increasingly adopted approach for resectable NSCLC.
- Chemoradiation + durvalumab: For unresectable Stage III NSCLC, concurrent chemoradiation followed by up to 12 months of durvalumab has become the standard of care.
- Targeted therapy + chemotherapy: In some cases, targeted agents may be combined with chemotherapy for enhanced effect.
Side Effects & Management
All cancer treatments can cause side effects. The type and severity depend on the treatment used, the dose, and the individual patient. Understanding potential side effects can help you prepare, communicate with your care team, and take steps to manage them. [NCI]
Fatigue
The most common side effect across nearly all lung cancer treatments. Cancer-related fatigue is different from normal tiredness — it is persistent and not fully relieved by rest. Management includes pacing activities, gentle exercise (shown to reduce fatigue), good nutrition, and treating contributing factors like anemia or depression. Tell your care team if fatigue is significantly affecting your daily life. [ACS]
Appetite Loss and Weight Changes
Chemotherapy, radiation to the chest, and the cancer itself can reduce appetite, alter taste, and cause nausea. Eating small, frequent meals, working with a dietitian, and using anti-nausea medications prescribed by your team can help. Maintaining nutrition is important for healing and tolerating treatment. [NCI]
Breathing Changes
Surgery that removes part or all of a lung will permanently reduce lung capacity. Radiation to the chest can cause pneumonitis (inflammation of the lung) weeks to months after treatment. Immunotherapy can also cause pneumonitis. Pulmonary rehabilitation, breathing exercises, and prompt reporting of new breathing difficulty are essential. [ACS]
Neuropathy (Nerve Damage)
Some chemotherapy drugs (especially platinum agents and taxanes) can damage peripheral nerves, causing tingling, numbness, or pain in the hands and feet. This is called chemotherapy-induced peripheral neuropathy (CIPN). It may improve after treatment ends, but in some cases it can be long-lasting. Let your oncologist know if you notice symptoms — dose adjustments may help prevent worsening. [NCI]
Immune-Related Adverse Events (irAEs)
Immunotherapy works by activating the immune system, which can sometimes cause the immune system to attack healthy organs and tissues. Common immune-related side effects include: [NCCN]
- Skin reactions: Rash, itching, vitiligo
- Colitis: Diarrhea, abdominal pain
- Hepatitis: Elevated liver enzymes, jaundice
- Pneumonitis: Cough, shortness of breath (requires urgent attention)
- Thyroid problems: Hypothyroidism or hyperthyroidism
- Endocrinopathies: Adrenal insufficiency, type 1 diabetes (rare)
Immune-related side effects are usually manageable if caught early. Report any new or worsening symptoms promptly to your care team. Treatment may involve corticosteroids or temporary pausing of immunotherapy. [NCCN]
Side Effects of Targeted Therapy
Side effects vary by drug class but may include skin rashes and acne-like eruptions (EGFR inhibitors), visual disturbances (ALK inhibitors), liver enzyme elevations, diarrhea, muscle and joint pain, and fatigue. Most targeted therapy side effects are manageable with dose adjustments and supportive medications. [NCCN]
Living With Lung Cancer
Stigma and Smoking Blame
Lung cancer carries a unique stigma. Many patients report being asked "Did you smoke?" as one of the first questions after their diagnosis — a question rarely asked of people with other cancers. This blame can come from well-meaning friends, family, or even healthcare providers, and it causes real psychological harm. [ALA]
The truth is: anyone with lungs can get lung cancer. While smoking is the primary risk factor, 10–20% of lung cancers occur in people who have never smoked. And even for those who did smoke, they deserve the same compassion, quality of care, and freedom from blame as any other cancer patient. Smoking is an addiction, not a moral failing. Lung cancer stigma reduces research funding, discourages screening, and isolates patients when they most need support. [ALA]
Breathing Exercises and Pulmonary Rehabilitation
Breathing exercises can help manage shortness of breath and improve quality of life. Techniques include:
- Diaphragmatic breathing: Breathing deeply from the diaphragm rather than shallow chest breathing. Place one hand on your chest and one on your abdomen — the hand on your abdomen should rise more.
- Pursed-lip breathing: Inhale slowly through the nose, then exhale slowly through pursed lips (as if blowing out a candle). This helps keep airways open longer.
- Pulmonary rehabilitation: A supervised program of exercise, education, and support that can significantly improve breathing, endurance, and quality of life, especially after surgery. Ask your care team for a referral. [ALA]
Palliative Care
Palliative care is specialized medical care focused on providing relief from symptoms, pain, and the stress of serious illness. It is not the same as hospice or end-of-life care. Palliative care can be given alongside curative treatment at any stage of illness. Studies have shown that early palliative care for lung cancer patients can improve quality of life, reduce depression, and may even improve survival. Ask your oncologist about integrating palliative care into your treatment plan from the start. [NCI]
Mental Health
A cancer diagnosis can cause significant emotional distress, including anxiety, depression, grief, and fear. For lung cancer patients, the added burden of stigma can compound these feelings. Mental health support is not a luxury — it is an essential part of cancer care.
- Talk to your care team about how you are feeling emotionally. Many cancer centers have psychologists, social workers, or psychiatrists on staff.
- Support groups — in person or online — can connect you with others who understand what you are going through.
- Counseling and therapy (including cognitive behavioral therapy) can provide coping strategies.
- Medication for anxiety or depression may be appropriate and can be prescribed alongside cancer treatment.
- Mindfulness and stress reduction techniques have been shown to help cancer patients manage emotional distress. [NCI, ACS]
Questions to Ask Your Doctor
Walking into an appointment with a list of questions helps you stay informed, reduces anxiety, and ensures nothing important is missed. Copy these questions or bring this page with you.
At Diagnosis
Before Treatment
During Treatment
After Treatment
Sources & References
Every claim on this page is grounded in peer-reviewed research and clinical guidelines from major cancer organizations. The following sources were used throughout this guide.
-
World Health Organization (WHO). "Lung Cancer Fact Sheet." World Health Organization.
https://www.who.int/news-room/fact-sheets/detail/lung-cancer -
American Cancer Society (ACS). "Lung Cancer Overview." American Cancer Society.
https://www.cancer.org/cancer/types/lung-cancer.html -
National Cancer Institute (NCI). "Lung Cancer Treatment (PDQ) — Patient Version." National Institutes of Health.
https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq -
National Comprehensive Cancer Network (NCCN). "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer." NCCN.
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf -
American Lung Association (ALA). "Lung Cancer Screening." American Lung Association.
https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan -
U.S. Preventive Services Task Force (USPSTF). "Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2021;325(10):962–970.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening -
Herbst RS, Morgensztern D, Boshoff C. "The biology and management of non-small cell lung cancer." Nature. 2018;553(7689):446–454.
https://doi.org/10.1038/nature25183
Last reviewed: January 2025. Sources are cited for educational context. This page is not medical advice. Treatment decisions should always be made in consultation with your healthcare team based on your individual circumstances. StopMyCancer does not endorse any specific treatment, drug, or healthcare provider.